We approached this subject by investigating FLT3/ITD+ in de novo AML patients categorized according to cytogenetic results, focusing especially on the group with favorable prognosis and normal karyotype, and associating this with age and white blood cell (WBC) count. This evidence concerns the gene FLT3 and acute myeloid leukemia.